In The Know-November 2022

November 2022
Pdf Summary
Ed's List: Gynecologic Oncology Literature of Significance (November 2022 - October 2022)<br /><br />Here are some key studies and findings from the field of gynecologic oncology:<br /><br />1. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs: This study examines the association between the cost and efficacy of cancer drugs approved by the FDA between 2015 and 2020. It suggests that the value of cancer drugs may not align with their high cost.<br /><br />2. Non-viral precision T cell receptor replacement for personalized cell therapy: This clinical trial tested a new approach using CRISPR/Cas9 non-viral precision genome editing to enhance T cells for personalized cell therapy in patients with refractory solid cancers.<br /><br />3. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition: This study identifies a potential target cascade for improving the response to PARP inhibitors in ovarian and breast tumors.<br /><br />4. Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes: This study identifies molecular subclasses of clear cell ovarian carcinoma and evaluates their impact on clinical presentation and outcomes.<br /><br />5. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers: This study identifies a mutational signature that can predict responses to the PARP inhibitor olaparib in breast and ovarian cancers.<br /><br />6. Long-term survival of nonlocalized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis: This study investigates the long-term survival benefits of menopausal hormone therapy in women with nonlocalized ovarian cancer.<br /><br />7. Association of Physician Densities and Gynecologic Cancer Outcomes in the United States: This study examines the association between the density of obstetrician-gynecologists and primary care physicians and gynecologic cancer outcomes in the United States.<br /><br />8. Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer: This study characterizes the genetic, epigenetic, and transcriptomic features of high-grade serous ovarian cancer at the single-cell level.<br /><br />9. Active expectancy as an alternative to treatment for cervical intraepithelial neoplasia grade 2 in women aged 25 to 30 years: This study evaluates the natural course of untreated cervical intraepithelial neoplasia grade 2 in young women and its association with human papillomavirus 16.<br /><br />10. Cervical Cancer Prevention and Cost for Women Older Than 65 Years in the US: This study assesses the use and cost of cervical cancer screening-associated services in women over the age of 65 in the United States.<br /><br />These studies provide insights into various aspects of gynecologic oncology and have implications for improving diagnosis, treatment, and outcomes in patients with gynecologic cancers.
Keywords
Gynecologic Oncology
Oncology Drugs
Precision T Cell Receptor Replacement
PARP Inhibition
Molecular Subclasses of Clear Cell Ovarian Carcinoma
Mutational Signature 3
Nonlocalized Epithelial Ovarian Cancer
Physician Densities
High-Grade Serous Ovarian Cancer
Cervical Cancer Prevention